Literature DB >> 11494141

Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.

M Unoki1, Y Nakamura.   

Abstract

Defects in PTEN, a tumor suppressor, have been found in cancers arising in a variety of human tissues. To elucidate the tumor-suppressive function of this gene, we have been analysing expression profiles of cancer cells after introduction of exogenous PTEN. Those experiments identified 99 candidate genes that were transcriptionally transactivated. Among them, we report here the further analyses of eight genes, EGR2/Krox-20, BPOZ, APS, HCLS1/HS1, DUSP1/MKP1, NDRG1/Drg1/RTP, NFIL3/E4BP4, and a novel gene (PINK1, PTEN-induced putative kinase). Expression of six of them (PINK1, EGR2, HCLS1, DUSP1, BPOZ, and NFIL3) was decreased in ovarian tumors compared with corresponding normal tissues. Colony-formation assays using plasmid clones designed to express each gene indicated that EGR2 and BPOZ were able to suppress growth of cancer cells significantly; in particular, cancer-cell lines stably expressing BPOZ grew more slowly than control cells containing mock vector. Flow cytometry suggested that over-expression of BPOZ inhibited progression of the cell cycle at the G(1)/S transition. Anti-sense oligonucleotides for BPOZ or EGR2 effectively inhibited their expression, and cell growth was accelerated. Therefore both genes appear to be novel candidates as mediators of the PTEN growth-suppressive signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494141     DOI: 10.1038/sj.onc.1204608

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  126 in total

1.  Calcium-dependent upregulation of E4BP4 expression correlates with glucocorticoid-evoked apoptosis of human leukemic CEM cells.

Authors:  Saul J Priceman; Jonathan D Kirzner; Laura J Nary; Devin Morris; Deepa B Shankar; Kathleen M Sakamoto; Rheem D Medh
Journal:  Biochem Biophys Res Commun       Date:  2006-04-05       Impact factor: 3.575

2.  Pink1 kinase and its membrane potential (Deltaψ)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode.

Authors:  Dorothea Becker; Judith Richter; Maja A Tocilescu; Serge Przedborski; Wolfgang Voos
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

3.  Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin.

Authors:  Yufeng Yang; Stephan Gehrke; Yuzuru Imai; Zhinong Huang; Yingshi Ouyang; Ji-Wu Wang; Lichuan Yang; M Flint Beal; Hannes Vogel; Bingwei Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-03       Impact factor: 11.205

4.  Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP.

Authors:  M Emdadul Haque; Kelly J Thomas; Cheryl D'Souza; Steve Callaghan; Tohru Kitada; Ruth S Slack; Paul Fraser; Mark R Cookson; Anurag Tandon; David S Park
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-24       Impact factor: 11.205

5.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

6.  Toxoplasma gondii rhoptry discharge correlates with activation of the early growth response 2 host cell transcription factor.

Authors:  Eric D Phelps; Kristin R Sweeney; Ira J Blader
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 7.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

8.  Contractile activity attenuates autophagy suppression and reverses mitochondrial defects in skeletal muscle cells.

Authors:  Alexa Parousis; Heather N Carter; Claudia Tran; Avigail T Erlich; Zahra S Mesbah Moosavi; Marion Pauly; David A Hood
Journal:  Autophagy       Date:  2018-08-04       Impact factor: 16.016

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Merging mouse transcriptome analyses with Parkinson's disease linkage studies.

Authors:  Daniel Gherbassi; Lavinia Bhatt; Sandrine Thuret; Horst H Simon
Journal:  DNA Res       Date:  2007-05-23       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.